Year |
Citation |
Score |
2013 |
Zeller J, Turbiak AJ, Powelson IA, Lee S, Sun D, Showalter HD, Fearon ER. Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of β-catenin/TCF transcription. Bioorganic & Medicinal Chemistry Letters. 23: 5814-20. PMID 24060489 DOI: 10.1016/J.Bmcl.2013.08.111 |
0.478 |
|
2012 |
Gill SK, Xu H, Kirchhoff PD, Cierpicki T, Turbiak AJ, Wan B, Zhang N, Peng KW, Franzblau SG, Garcia GA, Showalter HD. Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases. Journal of Medicinal Chemistry. 55: 3814-26. PMID 22452568 DOI: 10.1021/Jm201716N |
0.487 |
|
2011 |
Okawada M, Koga H, Larsen SD, Showalter HD, Turbiak AJ, Jin X, Lucas PC, Lipka E, Hillfinger J, Kim JS, Teitelbaum DH. Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Digestive Diseases and Sciences. 56: 2553-65. PMID 21399927 DOI: 10.1007/S10620-011-1651-9 |
0.471 |
|
2010 |
Turbiak AJ, Hollis Showalter HD. A New Route to Substituted Pyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones and Facile Extension to 5,7(6H,8H) Isomers. Synthesis. 41: i. PMID 21243040 DOI: 10.1055/S-0029-1217030 |
0.386 |
|
2010 |
Turbiak AJ, Kampf JW, Hollis Showalter HD. A novel synthesis of 3-(substituted)pyrimido[4,5-c]pyridazine-5,7(1H,6H)-diones. Tetrahedron Letters. 51: 1326-1328. PMID 21103016 DOI: 10.1016/J.Tetlet.2010.01.007 |
0.359 |
|
2009 |
Turbiak AJ, Showalter HD. A novel synthesis of N(1)-(substituted)-pyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones. Tetrahedron Letters. 50: 1996-1997. PMID 21643441 DOI: 10.1016/J.Tetlet.2009.02.084 |
0.481 |
|
Show low-probability matches. |